MMV371

Janssen
Asexual blood stages
Chemoprevention

MMV371

Translational
-
Preclinical
Product vision

  • Prophylaxis
MOA

  • Prodrug; active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)
Key features

  • Long acting injectable

  • Prodrug of well-tolerated, marketed prophylactic drug (atovaquone)

  • High liver-stage potency
Challenges

  • Cost and feasibility of formulation
Status

  • Preclinical development - Good Laboratory Practice intra-muscular safety studies complete

  • CMC - Good Manufacturing Practice drug product manufacture ongoing
Next milestone
  • Start of first-in-human phase I clinical study 2023
Previously
  • Discovery partnership between MMV and Calibr
  • Name: mCBE161
Project Director

  • Dr Andrew Slade